• Oct 5, 2026

  $310.77+7.09%

  Comparable listed companies in commercial physical and biological research rose 1.85% on average, with 2 of 3 rising [1]. The company's 7.09% gain was well above that cohort average, so the move was only partly shared by the group [1].

  • 1Peer group

• Oct 2, 2026

  $290.19+1.17%

  Comparable listed companies in commercial physical and biological research fell 0.77% on average, with 2 of 3 lower [1]. CRL rose 1.17%, so its gain was not shared by the cohort. Volume was 0.5x its trailing 20-session average, and the session range was 1.7% of the low [2].

  • 1Peer group
  • 2Market data

• Oct 1, 2026

  $286.83-2.77%

  The shares fell 2.77% alongside comparable listed companies in commercial physical and biological research, which fell 3.56% on average, with all 3 of 3 lower [1].

  • 1Peer group

• Sep 30, 2026

  $295.01-0.32%

• Sep 29, 2026

  $295.96+0.47%

• Sep 28, 2026

  $294.59+0.60%

• Sep 25, 2026

  $292.84-0.54%

  Comparable companies in Services-Commercial Physical & Biological Research fell 0.80% on average, with all three peers declining [1]. Charles River's decline came alongside that broader move among its peers [1].

  • 1Peer group

Closing prices for CRL. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.